DK3182962T3 - Compositions and uses of amidine derivatives - Google Patents

Compositions and uses of amidine derivatives Download PDF

Info

Publication number
DK3182962T3
DK3182962T3 DK15756791.8T DK15756791T DK3182962T3 DK 3182962 T3 DK3182962 T3 DK 3182962T3 DK 15756791 T DK15756791 T DK 15756791T DK 3182962 T3 DK3182962 T3 DK 3182962T3
Authority
DK
Denmark
Prior art keywords
compositions
amidine derivatives
amidine
derivatives
Prior art date
Application number
DK15756791.8T
Other languages
Danish (da)
English (en)
Inventor
Vivekanand P Kamath
Yarlagadda S Babu
Walter Gowan
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Application granted granted Critical
Publication of DK3182962T3 publication Critical patent/DK3182962T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Treating Waste Gases (AREA)
DK15756791.8T 2014-08-22 2015-08-24 Compositions and uses of amidine derivatives DK3182962T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462040836P 2014-08-22 2014-08-22
PCT/US2015/046578 WO2016029214A1 (en) 2014-08-22 2015-08-24 Compositions and uses of amidine derivatives

Publications (1)

Publication Number Publication Date
DK3182962T3 true DK3182962T3 (da) 2023-09-18

Family

ID=54012341

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15756791.8T DK3182962T3 (da) 2014-08-22 2015-08-24 Compositions and uses of amidine derivatives

Country Status (8)

Country Link
US (1) US10905683B2 (enExample)
EP (1) EP3182962B1 (enExample)
JP (1) JP6824876B2 (enExample)
AU (1) AU2015305214B2 (enExample)
CA (1) CA2959026C (enExample)
DK (1) DK3182962T3 (enExample)
ES (1) ES2954451T3 (enExample)
WO (1) WO2016029214A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
HUE049918T2 (hu) 2016-05-31 2020-11-30 Kalvista Pharmaceuticals Ltd Pirazol-származékok mint plazma kallikrein inhibitorok
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106565442B (zh) * 2016-08-24 2019-07-16 浙江美诺华药物化学有限公司 3-(3-氟苄基)-4-(3-氟苄氧基)苯甲醛的制备方法
CN106632223B (zh) * 2016-08-24 2019-04-23 浙江美诺华药物化学有限公司 2-(3-溴-4-(3-氟苄氧基)苯基)-1,3-二氧戊环及其制备方法
US10759759B2 (en) 2016-10-31 2020-09-01 Biocryst Pharmaceuticals, Inc. Prodrugs of kallikrein inhibitors
CN106977382A (zh) * 2017-04-28 2017-07-25 山东新华制药股份有限公司 4‑（3‑氟苄氧基）苯甲醛的制备方法
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
SI3716952T1 (sl) 2017-11-29 2022-04-29 Kalvista Pharmaceuticals Limited Farmacevtske oblike, ki obsegajo zaviralec plazemskega kalikreina
AU2020273154A1 (en) * 2019-04-08 2021-12-02 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
WO2022006232A2 (en) * 2020-07-01 2022-01-06 The Board Of Trustees Of The Leland Stanford Junior University Drug repurposing for treatment of viral infections
AU2021427558A1 (en) * 2021-02-09 2023-08-31 Phebra Pty Ltd Method of preparing a topical pharmaceutical composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1540979A (en) 1923-04-11 1925-06-09 Swift & Co Machine for testing jelly strength of glues, gelatins, and the like
CA2426430C (en) 2000-10-20 2014-10-07 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
RU2003132706A (ru) * 2001-04-06 2005-04-20 Байокрист Фармасьютикалз, Инк. (Us) Диариловые соединения в качестве ингибиторов сериновых протеаз
CA3061802C (en) * 2011-09-08 2022-04-05 Intrexon Corporation Crystalline diacylhydrazine and the use thereof
WO2014057069A1 (en) 2012-10-10 2014-04-17 Novo Nordisk Health Care Ag Liquid pharmaceutical composition of factor vii polypeptide

Also Published As

Publication number Publication date
US20170266172A1 (en) 2017-09-21
JP2017525718A (ja) 2017-09-07
CA2959026A1 (en) 2016-02-25
WO2016029214A1 (en) 2016-02-25
ES2954451T3 (es) 2023-11-22
EP3182962A1 (en) 2017-06-28
AU2015305214A1 (en) 2017-03-16
US10905683B2 (en) 2021-02-02
EP3182962B1 (en) 2023-06-07
WO2016029214A9 (en) 2017-01-05
AU2015305214B2 (en) 2020-04-23
CA2959026C (en) 2023-10-24
JP6824876B2 (ja) 2021-02-03

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
DK3182962T3 (da) Compositions and uses of amidine derivatives
IL280863A (en) Autotaxin inhibitors and uses thereof
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
KR20180084891A (ko) 구조 조성물 및 방법
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
LT3102555T (lt) Junginių kompozicijos ir jų panaudojimas
KR102061390B9 (ko) 구아니딘 화합물 및 그의 용도
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
EP3386505A4 (en) AZA-BENZIMIDAZOLINHIBITORS OF PAD4
PL3457851T3 (pl) Pochodne sobetiromu
DK3132009T3 (da) Fremgangsmåde
PL3154515T3 (pl) Udoskonalenia kompozycji donosowych i sposób ich stosowania
DK3283210T3 (da) Fremgangsmåde
PT3261437T (pt) Compostos e composições fungicidas
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3418273T3 (da) Derivater af flavagliner
DE112015003841A5 (de) Di- und triphosphat-propharmaka
IL254502A0 (en) Solid forms of menaquinols
IL258630A (en) Formulation of l-ornithine phenylacetate
DK3173071T3 (da) Formularing af maropitant
FI20145117A7 (fi) Stabiloitu liima-aineformulaatio
DK3148513T3 (da) Ceritinib-formulering
FR3024647B1 (fr) Transat de puericulture